Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥37.78 Million ≈ $5.53 Million USD) by net assets (CN¥1.05 Billion ≈ $153.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Zhuhai Rundu Pharmaceutical Co Ltd Class's balance sheet to measure how much of total assets are equity-financed.
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Zhuhai Rundu Pharmaceutical Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 002923 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhuhai Rundu Pharmaceutical Co Ltd Class A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Comp SA
WAR:CMP
|
0.041x |
|
Dutch Lady Milk Industries Bhd
KLSE:3026
|
0.002x |
|
Investors Title Company
NASDAQ:ITIC
|
0.006x |
|
VRL Logistics Limited
NSE:VRLLOG
|
0.305x |
|
United States Cellular Corporation
NYSE:USM
|
-0.100x |
|
Xiamen Sunrise Wheel Group Co Ltd
SHE:002593
|
0.028x |
|
Shenzhen Aoto Electronics Co Ltd
SHE:002587
|
0.013x |
|
Sunrise Energy Metals Ltd
AU:SRL
|
-0.278x |
Annual Cash Flow Conversion Efficiency for Zhuhai Rundu Pharmaceutical Co Ltd Class A (2011–2024)
The table below shows the annual cash flow conversion efficiency of Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Zhuhai Rundu Pharmaceutical Co Ltd Class (002923) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.15 Billion ≈ $168.59 Million |
CN¥211.19 Million ≈ $30.90 Million |
0.183x | +25.17% |
| 2023-12-31 | CN¥1.18 Billion ≈ $172.55 Million |
CN¥172.68 Million ≈ $25.27 Million |
0.146x | +29.73% |
| 2022-12-31 | CN¥1.20 Billion ≈ $175.01 Million |
CN¥135.01 Million ≈ $19.76 Million |
0.113x | -39.03% |
| 2021-12-31 | CN¥1.11 Billion ≈ $162.74 Million |
CN¥205.91 Million ≈ $30.13 Million |
0.185x | -23.22% |
| 2020-12-31 | CN¥1.04 Billion ≈ $151.93 Million |
CN¥250.35 Million ≈ $36.63 Million |
0.241x | +49.86% |
| 2019-12-31 | CN¥940.29 Million ≈ $137.59 Million |
CN¥151.30 Million ≈ $22.14 Million |
0.161x | -11.85% |
| 2018-12-31 | CN¥871.29 Million ≈ $127.50 Million |
CN¥159.04 Million ≈ $23.27 Million |
0.183x | +53.97% |
| 2017-12-31 | CN¥488.84 Million ≈ $71.53 Million |
CN¥57.95 Million ≈ $8.48 Million |
0.119x | -49.82% |
| 2016-12-31 | CN¥398.19 Million ≈ $58.27 Million |
CN¥94.07 Million ≈ $13.77 Million |
0.236x | +46.41% |
| 2015-12-31 | CN¥310.72 Million ≈ $45.47 Million |
CN¥50.14 Million ≈ $7.34 Million |
0.161x | -23.98% |
| 2014-12-31 | CN¥273.31 Million ≈ $39.99 Million |
CN¥58.01 Million ≈ $8.49 Million |
0.212x | +58.34% |
| 2013-12-31 | CN¥236.29 Million ≈ $34.58 Million |
CN¥31.67 Million ≈ $4.63 Million |
0.134x | -61.82% |
| 2012-12-31 | CN¥199.43 Million ≈ $29.18 Million |
CN¥70.01 Million ≈ $10.25 Million |
0.351x | +72.18% |
| 2011-12-31 | CN¥165.33 Million ≈ $24.19 Million |
CN¥33.71 Million ≈ $4.93 Million |
0.204x | -- |
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, qu… Read more